In short
Clinical trials are studying Azd0305 in adults with multiple myeloma. These studies aim to check safety, tolerability, and early signs of benefit, both when Azd0305 is used alone and with other cancer treatments.
Key points
- Azd0305 is being studied in a Phase 1/2 clinical trial for adults with multiple myeloma. The trial is looking at Azd0305 used by itself and together with other cancer treatments. Researchers want to learn about safety, tolerability, and the recommended Phase 2 dose. The study also measures dose-limiting toxicities, adverse events, and serious adverse events. The trial is authorised and plans to enroll 292 participants.
Trial overview
The available trial information shows one interventional study of Azd0305 in adults with multiple myeloma, a cancer of plasma cells in the bone marrow. The study is authorised, is in Phase 1/2, and plans to enroll 292 participants.
Who can participate
This trial is for adults with multiple myeloma. The source data provided here does not list all inclusion and exclusion rules, so the full eligibility details are not shown in this summary.
What is being studied
Researchers are studying Azd0305 alone and in combination with other cancer treatments. The listed study drugs include pomalidomide taken by mouth and elranatamab given by subcutaneous injection, which means an injection under the skin.
The main goal is to assess safety and tolerability and to find the Recommended Phase 2 Dose (RP2D) of Azd0305 in these treatment settings. In simple terms, the study is trying to learn what dose may be suitable for later testing and whether the treatment can be given safely.
Study phase and design
This is a Phase 1/2 study, which usually means the research starts by focusing on safety and dose, then moves toward early testing of how well the treatment may work. The trial is also described as interventional, meaning participants receive a study treatment rather than only being observed.
The trial title says it is designed to learn whether Azd0305 alone and with other cancer treatments is safe and works in adults with multiple myeloma. This tells patients that the study is not only about safety, but also about early signs of benefit.
Outcomes being measured
The main outcome in the early dose-escalation part is dose-limiting toxicities, which are side effects serious enough to stop the dose from being increased. The study also measures the incidence and severity of adverse events and serious adverse events, meaning how often unwanted health problems happen and how bad they are.
The brief summary says the study is also trying to determine the RP2D of Azd0305 as a single treatment and in combination with other anticancer agents. Module-specific endpoints are mentioned in the source, but they are not listed in the provided data.
Key terms explained
Multiple myeloma is a cancer that affects plasma cells, which are part of the immune system. Subcutaneous injection means a shot given under the skin, and intravenous infusion means a medicine given through a vein. Oral treatment means a medicine taken by mouth.
Adverse events are any unwanted health problems seen during a study, while serious adverse events are the more severe ones, such as those that are life-threatening or need hospital care.